The Center for Hematologic Oncology at Dana-Farber/Brigham and Women's Cancer Center is one of the largest programs in the U.S. for patients with hematologic malignancies. We see more than 12,500 patients
each year from around the world, and we offer specialized expertise in:
- Acute and chronic leukemia
- Chronic lymphocytic leukemia (CLL)
- Aggressive lymphoma
- Low-grade lymphoma
- Autologous and allogeneic stem cell transplant
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- Multiple myeloma
- Precursor conditions
- Waldenström's macroglobulinemia
- Cellular therapies such as CAR T-cell therapy
Our faculty and staff are actively engaged in basic, translational, and clinical research to improve outcomes and quality of life for patients. We offer more than 200 clinical trials evaluating new therapies — making us the first to offer the most promising
treatments to patients.
Why Choose DF/BWCC for Stem Cell Transplant or CAR T-Cell Therapy
Our Stem Cell Transplant and Cellular Therapies Program has more than 45 years of experience and is one of the largest in the world, having performed more than 10,600 transplants. This experience makes a difference:
- In-depth knowledge: We understand how to manage the complex treatment plans and unique needs associated with transplant and other cellular therapies.
- Extensive evaluation: Our team carefully evaluates each patient to determine if stem cell transplant or CAR T-cell therapy is appropriate.
- Exceptional outcomes: Our stem cell transplant outcomes consistently exceed the expected outcomes as established by the Center for International Blood and Marrow Transplant Research (CIBMTR).
- Large team: We have more than 35 transplant-credentialed physicians. All are Harvard Medical School faculty members.
- Disease-specific expertise: We offer stem cell transplant for many types of blood cancer and blood disorders, including leukemias, lymphomas, multiple myeloma, myelodysplastic syndromes, aplastic anemia, sickle cell disease, and more.
Learn more about the diseases we treat with stem cell transplant.
- Novel approaches: Our Center offers all FDA-approved CAR T-cell therapies, as well as clinical trials exploring this CAR T and other cellular therapies for blood cancers and solid tumors.
- State-of-the-art, in-house cell processing lab: The Connell and O'Reilly Families Cell Manipulation Core Facility is a critical
component to our program, processing cellular products for stem cell transplant and CAR T-cell therapies.
- Strong partnerships: Dana-Farber partners with Brigham and Women's Hospital, one of the nation's leading hospitals, to care for patients. In addition to a dedicated transplant or cellular therapy physician and nurse practitioner,
patient care may include expert specialists in infectious disease, dermatology, neurology, pulmonology, and more – all with a deep understanding of the complex needs and complications of patients receiving these advanced therapies.
What We Offer to International Patients
From exceptional medical care to support with housing and other logistics, we offer many services to international patients:
- Remote consults and online second opinions to evaluate a diagnosis or recommended treatment plans/options
- Advanced diagnostic testing, including the Rapid Heme Panel, an advanced DNA sequencing
tool unique to DF/BWCC
- Assistance with housing and transportation for patients and caregivers
- Support with logistics, such as travel visas, medical records transfer, financial estimates, and billing
- Patient navigators who accompany patients to appointments
- Interpreter services
- Extensive patient education materials in print, online, and video formats, many of which are translated for non-English
speaking patients and caregivers
- Nutrition services, with attention to special dietary needs
- Dedicated social work resources
Our physician, nursing, and administrative teams are leaders in national and international organizations, working to influence policy and improve standards of care.
Robert J. Soiffer, MD
Chief, Division of Hematologic Malignancies
Vice Chair, Department of Medical Oncology
Catherine Wu, MD
Chief, Division of Stem Cell Transplantation and Cellular Therapies
Stem Cell Transplant Leadership
Joseph Antin, MD
Chief, Stem Cell Transplantation Emeritus
Corey Cutler, MD, MPH, FRCPC
Medical Director, Stem Cell Transplantation
Director of Clinical Research, Stem Cell Transplantation
Director, Stem Cell Transplantation Survivorship Program
Vincent Ho, MD
Director of Clinical Operations, Stem Cell Transplantation
John Koreth, MBBS, DPhil
Director of Translational Research, Stem Cell Transplantation
Rizwan Romee, MD
Director, Haploidentical Transplantation Program
Amy Emmert, MScPH
Executive Director for Cellular Therapy External Affairs
Janet Bagley, RN, MS
Associate Chief Nurse
Vice President of Cellular Therapy Operations
Meet Our Stem Cell Transplant Team.
Cellular Therapies Leadership
Caron Jacobson, MD
Medical Director, Immune Effector Cell Therapy Program
Sarah Nikiforow, MD, PhD
Technical Director, Immune Effector Cell Therapy Program
Medical Director, Connell and O'Reilly Families Cell Manipulation Core Facility
Jerome Ritz, MD
Executive Director, Connell and O'Reilly Families Cell Manipulation Core Facility
Linda Caruso, NP
Assistant Program Director, Immune Effector Cell Therapy Program
How to Refer a Patient
We work with our partners in the Brigham and Women's Hospital International Office to coordinate referrals for international patients. Contact
us to inquire about an appointment:
Post-Treatment Care and Coordination
Care for stem cell transplant or CAR T-cell therapy patients continues long after they are discharged from the hospital and return home to your care. We provide physicians with post-discharge care guidelines that outline recommended testing, symptoms
to monitor, re-immunizations, and more — all to help you care for your returning patients. And our physicians will remain available to consult with you and answer any questions about post-discharge care.